Featured Publications
Annual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment‐resistant depression. Journal Of Child Psychology And Psychiatry 2020, 61: 312-332. PMID: 32020643, PMCID: PMC8314167, DOI: 10.1111/jcpp.13202.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionMajor depressive disorderAdolescent treatment-resistant depressionRisk factorsAdolescent major depressive disorderPsychotherapy treatment trialSecond-line treatmentSignificant risk factorsPediatric clinical trialsSecond leading causeSignificant health problemEvidence-based psychotherapiesCent of adolescentsMedication switchAdequate medicationSubstantial morbiditySymptom improvementInterventional treatmentMedication augmentationTreatment trialsCare treatmentClinical trialsDepressive disorderDiagnostic difficultiesLeading cause
2024
Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 73-79. PMID: 38170185, PMCID: PMC11262580, DOI: 10.1089/cap.2023.0047.Peer-Reviewed Original ResearchDepression symptom improvementTreatment-resistant depressionChildren's Depression Rating ScaleReuptake inhibitor medicationsDepression Rating ScaleSymptom improvementAntidepressant responseInhibitor medicationKetamine responseAdolescent treatment-resistant depressionRapid-acting antidepressant agentsSelective serotonin reuptake inhibitor medicationsSerotonin reuptake inhibitor medicationsKetamine’s antidepressant responseCurrent depressive episodeSevere depressive symptomsGreater symptom improvementAttention-deficit/hyperactivity disorder diagnosisFuture therapeutic useAntidepressant medicationMedication trialsCrossover trialAntidepressant agentsClinical variablesDepressive episode
2023
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design
2021
Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials
Nasir M, Li F, Courley S, Olten B, Bloch MH. Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials. Journal Of Child And Adolescent Psychopharmacology 2021, 31: 670-684. PMID: 34558984, DOI: 10.1089/cap.2021.0030.Peer-Reviewed Original ResearchConceptsPlacebo response ratesObsessive-compulsive disorderPlacebo responseDepression trialsResponse ratePlacebo improvementSymptom improvementAntidepressant trialsStratified subgroup analysisRandom-effects modelPediatric populationSubgroup analysisStudy visitNumber of subjectsPsychopharmacological trialsPubMed searchDifferent indicationsDiagnostic indicationsMean differenceAnxiety disordersTrialsDisordersPediatric anxietyPredictorsPossible correlates
2020
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Appel S, Eli M, Alexander-Bloch A, Maayan L, Gur RE, Bloch MH. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2020, 31: 46-52. PMID: 32633541, PMCID: PMC7891207, DOI: 10.1089/cap.2020.0030.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementClinical responseEarly Onset Schizophrenia Spectrum Disorders StudySymptom improvementWeek 8Early-onset schizophrenia spectrum disordersClinical response timeWeeks of treatmentProportional hazards regressionDisorders StudyTime courseSchizophrenia spectrum disordersClinical nonresponseMedication differencesClinical respondersTreatment initiationClinical nonrespondersMedian timeHazards regressionAntipsychotic treatmentEarly improvementSchizoaffective disorderClinical judgmentMore weeksYouth ages 8
2019
Meta-Analysis of Placebo Response in Adult Antidepressant Trials
Li F, Nasir M, Olten B, Bloch MH. Meta-Analysis of Placebo Response in Adult Antidepressant Trials. CNS Drugs 2019, 33: 971-980. PMID: 31573058, DOI: 10.1007/s40263-019-00662-y.Peer-Reviewed Original ResearchConceptsPlacebo response ratesPlacebo improvementSymptom improvementObsessive-compulsive disorderResponse rateDiagnostic indicationsAntidepressant trialsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisSecond-generation antidepressantsPlacebo comparison groupFuture antidepressantsSubgroup analysisClinical trialsPlacebo responseTrial characteristicsGreater magnitudeDepression trialsMeta-AnalysisUS sitesTrial durationAntidepressantsLanguage limitsMean difference
2018
Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski E, Johnson JA, Nasir M, Müller‐Vahl K, Bloch MH. Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders. Depression And Anxiety 2018, 36: 198-212. PMID: 30479005, DOI: 10.1002/da.22854.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsGreater treatment benefitHigh dosesTreatment responseAnxiety disordersReuptake inhibitorsSymptom improvementTreatment benefitPharmacological agentsRandomized placebo-controlled clinical trialSSRIs/serotonin-norepinephrine reuptake inhibitorsPlacebo-controlled clinical trialIndividual pharmacological agentsCochrane Central RegisterNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsOverall symptom improvementGreater symptom improvementDose-response curveLinear mixed model analysisCentral RegisterMedication classesAdult patientsControlled Trials
2016
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal Of Clinical Psychiatry 2016, 77: e605-11. PMID: 27249090, DOI: 10.4088/jcp.14r09758.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsYale-Brown Obsessive Compulsive ScalePlacebo-controlled trialSerotonin reuptake inhibitorsTreatment of adultsObsessive-compulsive disorderSSRI responseSSRI treatmentReuptake inhibitorsSymptom improvementEfficacy of SSRIsTrials of SSRIsFirst-line pharmacologic treatmentCochrane Central RegisterStart of treatmentMajor depressive disorderEffect of doseObsessive Compulsive ScaleSSRI actionCentral RegisterPharmacologic treatmentPrimary outcomeControlled TrialsSSRI trialDepressive disorder
2014
Prognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. The Journal Of Clinical Psychiatry 2014, 75: 738-47. PMID: 24912106, PMCID: PMC4471174, DOI: 10.4088/jcp.13m08727.Peer-Reviewed Original ResearchConceptsMajor depressive disorderBaseline clinical characteristicsClinical characteristicsTreatment successTreatment outcomesTreatment responseSide effectsSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEarly symptom improvementInitial clinical characteristicsOpen-label citalopramPrimary outcome measureFirst treatment phasePast treatment historySequenced Treatment AlternativesDSM-IV diagnosisTraditional psychiatric diagnosesDifferential treatment outcomesSSRI treatmentSymptom improvementMDD patientsMedication responsePoor responseDepressive disorderPrognostic subgroups